AF
ITCI

Allworth Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Allworth Financial’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-424
Closed -$53.9K – 4204
2024
Q4 		$53.9K Buy
424
+46
+12% +$3.78K ﹤0.01% 1539
2024
Q3 		$27.7K Buy
378
+5
+1% +$376 ﹤0.01% 1708
2024
Q2 		$27.9K Buy
373
+4
+1% +$277 ﹤0.01% 1667
2024
Q1 		$25.5K Sell
369
-14
-4% -$962 ﹤0.01% 1629
2023
Q4 		$27.4K Buy
383
+96
+33% +$5.52K ﹤0.01% 1463
2023
Q3 		$14.9K Sell
287
-380
-57% -$22.1K ﹤0.01% 1692
2023
Q2 		$42.2K Buy
667
+340
+104% +$21.2K ﹤0.01% 1175
2023
Q1 		$17.7K Buy
327
+25
+8% +$1.21K ﹤0.01% 1529
2022
Q4 		$16K Buy
302
+35
+13% +$1.75K ﹤0.01% 1484
2022
Q3 		$12K Buy
267
+265
+13,250% +$13.8K ﹤0.01% 1586
2022
Q2 		$0 Sell
2
-9
-82% -$510 ﹤0.01% 2890
2022
Q1 		$1K Buy
+11
New +$571 ﹤0.01% 2044

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Allworth Financial's ITCI Position: Q1 2025 in Review

Allworth Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 424 shares — an estimated $53.9K sold.

Allworth Financial first reported a position in ITCI in Q1 2022 and held it in 12 quarters. The position peaked at $53.9K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Allworth Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Allworth Financial sold 424 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $53.9K.
  • Allworth Financial first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 12 quarters.
  • Allworth Financial's Intra-Cellular Therapies Inc. position peaked at $53.9K in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Allworth Financial's 13F filing for Q1 2025, filed 30 Apr 2025.